• Novo Nordisk will present obesity research across 26 abstracts at ObesityWeek 2026, November 14-17 in Washington, D.C.
• CagriSema presentations will examine weight loss at lower doses in REDEFINE 9 and weight-related quality of life in REDEFINE 1.
• Wegovy studies will assess real-world weight outcomes, food noise and patient experience with oral and injectable treatments.
• Full STEP Young results will cover investigational semaglutide injections for obesity in children ages 6 to under 12, with simultaneous publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.